catalyst · primary record
Cenerimod + Placebo
Phase readout · 2027-03-31 · Lupus Erythematosus, Systemic
| Company | Viatris Innovation GmbH |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT05648500 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:47.295Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Viatris Innovation GmbH:Cenerimod + Placebo:2027-03-31:P3 primary completion · NCT05648500
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.